http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6319562-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2474-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate | 1986-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fddb6e08738475d776814e8afb315802 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8437995695b67aec6d042cedd0bcd7c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef6a6c2d888d7f65ead9e54ed6b59a2c |
| publicationDate | 1988-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S6319562-A |
| titleOfInvention | Anti-lafora corpuscle monoclonal antibody |
| abstract | PURPOSE: To obtain an anti-Lafora corpuscle monoclonal antibody by immunizing a mouse with a Lafora disease parient's cardiac muscle homogenate or the abnormal glycogen extracted therefrom and preparing a hybridoma. n CONSTITUTION: The mammalian is immunized with the Lafora disease patient's cardiac muscle homogenate or the Lafora corpsucle extracted therefrom. The hybridoma is prepd. by fusing the spleen cells of the immunized animal and the myeloma cells of the mammalian. The hybridoma cell strain which reacts with the Lafora corpuscle is selected from such hybridoma cells and the cell strains are ascitized by the medium culture thereof or the intraperitoneal dosing of said cells to the mammalian. The monoclonal antibody which reacts with the Lafora corpuscle is accumulated in the culture matter or the ascites; thereafter, the monoclonal antibody is sampled, by which the anti-Lafora corpuscle monoclonal antibody effective for detecting the Lafora disease or glycogenosis type IV is obtd. n COPYRIGHT: (C)1988,JPO&Japio |
| priorityDate | 1986-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439177 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415966228 |
Total number of triples: 22.